Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time
Rhea-AI Summary
Shuttle Pharma (NASDAQ:SHPH) approved a 10-for-1 reverse stock split of its common stock, effective June 11, 2026 at 12:01 a.m. Eastern Time.
SHPH will trade on a split-adjusted basis that day, with issued shares reduced from 6,371,075 to approximately 637,108. No fractional shares will be issued; amounts will be rounded up. The split also adjusts RSUs, warrants, pre-funded warrants and convertible preferred stock, uses new CUSIP 825693500, and is intended to support Nasdaq listing compliance and long-term capital structure.
AI-generated analysis. Not financial advice.
Positive
- 10-for-1 reverse stock split effective June 11, 2026 at 12:01 a.m. ET
- Issued and outstanding shares reduced from 6,371,075 to approximately 637,108
- No fractional shares; entitlements rounded up to next whole share
- Reverse split intended to help maintain compliance with Nasdaq listing requirements
Negative
- None.
News Market Reaction – SHPH
On the day this news was published, SHPH declined 9.83%, reflecting a notable negative market reaction. Argus tracked a peak move of +9.4% during that session. Argus tracked a trough of -8.3% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $312K from the company's valuation, bringing the market cap to $2.86M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Pre-news, SHPH was moving against a backdrop of broader weakness, with 3 peers (RDHL, SBFM, INM) also in the momentum scanner, each moving down between about -4.5% and -19.5%.
Previous Stock split Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 12 | Reverse stock split | Negative | -34.4% | Announced 1-for-25 reverse split to cut float and maintain Nasdaq listing. |
| Jun 12 | Proposed stock split | Negative | -34.4% | Proposed 25-for-1 reverse split as part of Nasdaq compliance initiative. |
Prior reverse split announcements for SHPH coincided with sharp negative reactions of about -34.42%, suggesting investors have historically viewed these actions unfavorably.
Over the last year, SHPH has repeatedly used reverse stock splits to address Nasdaq listing pressure. In June 2025, a 1-for-25 reverse split reduced outstanding shares from about 26.2M to roughly 1.05M, framed as a move to maintain compliance and strengthen the capital structure. Both the proposed and effective 2025 reverse split announcements saw about -34.42% price reactions. Today’s 10-for-1 split fits this ongoing pattern of share consolidation to support Nasdaq requirements.
Historical Comparison
In the past year, SHPH announced 2 reverse splits tagged as 'stock split', with an average move of -34.42%. Today’s 10-for-1 action continues that compliance-driven pattern.
SHPH has progressed through multiple reverse splits (1-for-25 in 2025 to a new 10-for-1 in 2026), each framed as supporting Nasdaq compliance and capital structure stability.
Market Pulse Summary
The stock moved -9.8% in the session following this news. A negative reaction despite the mechanical nature of a 10-for-1 reverse split would fit SHPH’s history, where earlier stock-split announcements saw average moves of about -34.42%. With shares previously at 0.4842, far below the 1.92 200-day MA and -92.18% from the 52-week high, further downside could reflect concerns about repeated share consolidations, going-concern disclosures, and the large overhang from preferred and warrant structures.
Key Terms
reverse stock split financial
nasdaq capital market regulatory
cusip financial
rsu financial
warrants financial
pre-funded warrants financial
convertible preferred stock financial
AI-generated analysis. Not financial advice.
Gaithersburg, Maryland--(Newsfile Corp. - June 9, 2026) - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) ("Shuttle Pharma" or the "Company"), the owner of Molecule.ai, an artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development, and United Dogecoin, Inc., Shuttle Pharma's wholly owned subsidiary and a Dogecoin mining company, today announced that its board of directors have approved a proposed reverse stock split of its common stock at a ratio of 10-for-1. The reverse stock split will become effective on June 11, 2026, at 12:01 a.m., Eastern Time. The Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") under the existing symbol "SHPH" and will begin trading on a split-adjusted basis when the market opens on June 11, 2026. The new CUSIP number for the common stock following the reverse stock split will be 825693500.
At the effective time of the reverse stock split, every ten shares of the Company's issued and outstanding common stock will be automatically reclassified and combined into 1 share of common stock. This will reduce the number of issued and outstanding shares of common stock from 6,371,075 shares to approximately 637,108 shares, without giving effect to rounding. The split will also apply to Company common stock issuable upon the exercise of the Company's outstanding RSU grants, warrants, pre-funded warrants and convertible preferred stock. No fractional shares will be issued; instead, any fractional entitlements will be rounded up to the next highest whole number at the participant level.
The reverse stock split is part of Shuttle Pharma's strategic plan to maintain compliance with Nasdaq's continued listing requirements, while also strengthening the Company's long-term capital structure.
About Shuttle Pharmaceuticals
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) owns a pharmaceutical software artificial intelligence ("AI") driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai platform helps researchers explore the chemical space more efficiently, evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. For more information, please visit our website at www.shuttlepharma.com.
About United Dogecoin
United Dogecoin is a Dogecoin mining company built on three foundational advantages: scale, preferential access to best-in-class equipment, and an industry leading management team. Its mission is to establish and maintain category leadership in the Dogecoin sector through high-efficiency, low-cost mining operations and strategic coin accumulation, combining operational excellence, consistency and expert execution to build a robust reserve.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development of our company. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our ability to realize the anticipated benefits from the Molecule.ai platform, risks related to the acquisition and retention of future customers and our ability to generate revenue, our ability to fund our future operations, risks regarding our intellectual property, risks regarding our ability to maintain the listing of our common stock on Nasdaq, as well as other factors discussed in Shuttle Pharma's SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharma specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharma
Chris Cooper
Interim Chief Executive Officer
info@shuttlepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300646